Campbell & CO Investment Adviser LLC Chemo Centryx, Inc. Transaction History

Campbell & CO Investment Adviser LLC

$1.3 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 09, 2022	SELL	$15.36 - $27.51 $273,822 - $490,420	-17,827 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$22.22 - $39.12 $327,145 - $575,963	-14,723 Reduced 45.23%	17,827 $447,000
Q4 2021 Feb 10, 2022	BUY	$18.38 - $40.5 $598,269 - $1.32 Million	32,550 New	32,550 $1.19 Million
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $250,572 - $346,035	-5,059 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$47.25 - $65.16 $165,375 - $228,060	-3,500 Reduced 40.89%	5,059 $313,000
Q3 2020 Oct 15, 2020	BUY	$46.35 - $61.69 $13,858 - $18,445	299 Added 3.62%	8,559 $469,000
Q2 2020 Jul 29, 2020	BUY	$38.58 - $65.07 $318,670 - $537,478	8,260 New	8,260 $475,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

News

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.